{"name":"Artios Pharma Ltd","slug":"artios-pharma-ltd","ticker":"","exchange":"","domain":"artiospharma.com","description":"Artios Pharma Ltd is a biotechnology company focused on developing novel DNA damage response (DDR) inhibitors for the treatment of cancer. The company has a pipeline of three clinical-stage assets, with ART0380 in Phase 2 and ART4215 and ART6043 in Phase 1 trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ART6043","genericName":"ART6043","slug":"art6043","indication":"Other","status":"phase_1"},{"name":"ART4215","genericName":"ART4215","slug":"art4215","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ART0380","genericName":"ART0380","slug":"art0380","indication":"Advanced solid tumors (in combination with DNA-damaging chemotherapy)","status":"phase_2"}]}],"pipeline":[{"name":"ART6043","genericName":"ART6043","slug":"art6043","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ART0380","genericName":"ART0380","slug":"art0380","phase":"phase_2","mechanism":"ART0380 is a DNA-protein crosslink (DPC) repair inhibitor that enhances the activity of DNA damaging agents by preventing cellular repair of crosslinks.","indications":["Advanced solid tumors (in combination with DNA-damaging chemotherapy)"],"catalyst":""},{"name":"ART4215","genericName":"ART4215","slug":"art4215","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxQbDVCbVpqR1dDLVZNMzZ0WUV3TDZSSWJpZ21lWGxaUFk5M0kyZjhUeXd3SGNvSUlQeGdlMUdoamtyMV8xRlBJTmxadTNfVTZxeHFnMEdwMXhRM2NEd1RKSDQxQ0hVcC1HYWU3M2RoVl9YazNfREN3WmlFSlZoRVNUdTJsZWpvUENESHlGelJnRGFZdFpwcGlkZFVaVm9aNHY5S0FQN0tjTGpQTlZpSXowOXc2Qm1mWVNVVU5UOE9aWUJiRHpSd1p0TFY0WVp5OTlvZjk2Tnp5Zk1hU3BCRElST2lEc1VHTDVsNEViT0w2YWtheWRCcGVMMkR0TWhGOWJ4YU9tMkF3R3pObkxoQm1xTFMyazE1bVJ2MTI3Qmg0dHEwdjZXUTcyYzNFNWwtZlF2NEVIUmtwRDhMcVJjTzdEYU9Kak5iN3kzTmotVVNvOA?oc=5","date":"2026-02-23","type":"regulatory","source":"GlobeNewswire","summary":"Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer - GlobeNewswire","headline":"Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOOXdJRmpQZWVFeDN5OVJUMkU2VWJnakE2VWZaMU5VLXF4bWNXa3Y5RU5vbkxTb2pkY0FsVWFNZ1o5bV83RVpMVS1LZUdITnRFMndiUkFVY0todlNQd1JoZGZadzJuVnVzVjA4VHhEeFhGcVJQSnI2U0FaWkZwSmVKT3k3LVlGQmptTTNmY3Z2aVlIVjJxOUE?oc=5","date":"2026-02-16","type":"pipeline","source":"Yahoo Finance","summary":"Artios Strengthens Leadership Team to Accelerate Late-Stage Development of Potential First-in-Class Oncology Pipeline - Yahoo Finance","headline":"Artios Strengthens Leadership Team to Accelerate Late-Stage Development of Potential First-in-Class Oncology Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOMGV3RlF5VnhzaGhqWElnTmhXZHRkYWJ5Z1hKMUVoVVVLcUxPY0QtRVdsSGdPZWVmY1owRHlmbEFoOGk4Y1lHR1UxYTN2TEJlZDVoaDNkNGc5SkxBZ3Nyd0psOWtxaDQ4VU5hYk5Rd0NoSjhxR2xfei1TQXVPWWhJbi1TeHI4T3NwSllnM2xmTDAtMTI3cDFiTk1zRUt6dnoxOTZhc3UzNmlKUE9pRnRWSlBDSy1ibU1XSVc5VlZpd2J6cEVsRGR6a2ItQTg5eWJuMGNRMVVtaTI?oc=5","date":"2026-01-07","type":"pipeline","source":"GlobeNewswire","summary":"Artios to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire","headline":"Artios to Present at the 44th Annual J.P. Morgan Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQTHVjZXRSUVRFUUNOT1hpQ0Z3WEZrbTIzYWQxSmgxRWJCRlpCVXo3WEFHbWREMVlVWFlTRDNhYXhYYl8yamRLek14SUI4a3BPVjdFQU9QNlFlYUNFTzV5MzVWTE0yQU1WWXAxWFFZX1NEemVGZDdqczFNRXQzSFBBUi01S1FlRGFHYXBWS0h4X1JaSm8tQ0JTV1NCcGs4Uk9VbHBFa0VvMTk?oc=5","date":"2025-11-18","type":"pipeline","source":"Business Weekly","summary":"US investors heavily back Artios Pharma $115m Series D growth round - Business Weekly","headline":"US investors heavily back Artios Pharma $115m Series D growth round","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxQelhwcVFwODlJbEZPVEJkVThMeU1mdEItVXhnR2JnUUpJSUlhX0s0TjB5YUNkLU9BcHRGZkkzSG9RY01fTmgydG1rZjVkeDl1UUpaaEVSNjlLVzN5T3ZHY21veDJZV2pXVDZJSmZKQy0tRjE4SHAwQW16YWhGeWpwa1FYOE53elY0V2JhNjZZQjU4R2NIWFUzbWtkTHB1c2NHVW1iY29ReWduRTRyQ3BBSmdXWFZxQkdrT1g1RDZkcjRyMFdKOFBrQXNCbkoxemJPT3NibG1CdDlBNm54M3hmd2V6TFl6VTZTaGUtUjBEd0ZoTTdiVzhrRlVxRV9yb0xMMzI5aEZzRno3RUI1cjhTaHlnVmdpWm5mcVRYRGJsSnd1ZWxHaTlV?oc=5","date":"2025-11-17","type":"pipeline","source":"GlobeNewswire","summary":"Artios Announces Oversubscribed $115 Million Series D - GlobeNewswire","headline":"Artios Announces Oversubscribed $115 Million Series D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPX3RGdndablJSTkdwVUVPcmY5VFlHeTF2T1I3VjI3aE9YamFDUzk5YnUxUmxvNDRVOWRhOEtXSFlpTERadXMtalRCUU41RlNpcWhoU2RYLTYtVWdQeDF4aFY0WUI2d0Nod3BWTGpsTkt0NERsTDBlTU12azNNaWppaVZSNXdMMnh1RnFMV3VJcGpaMUZhcDFZMV9OdFZIRmllN2pib2ppRUhtOW9OMjVyeEVDREZmU1BtMHd3?oc=5","date":"2025-11-17","type":"pipeline","source":"EU-Startups","summary":"€99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline - EU-Startups","headline":"€99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline - EU","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOTmZvQ1JrdWpIQkpEekJsWWNzbWRSUVpoaDhnSUJtODgxSzA5dmN4NDBrcFhRY2NsYlR5UjdpTG1wMEswTWR3Tm01VTd4a0UxV25Ib282VG5xMTd6NHRoODJTOUJ1ZEFoRXdTV0VGb0tSZHB0a1hCSXZUX0dMZmZMWXZ5aGtRS2RzZl9DcEJVRkJhT3dyWmkzSEJLWjY3a2JoYlBUbGI2eU5Nc3h6TmJQQ3FRRnBiZWpNdHFCM1QyQ1d2OFk?oc=5","date":"2025-11-17","type":"pipeline","source":"Fierce Biotech","summary":"Artios Pharma secures $115M series D to ramp up clinical efforts with DNA damage response pipeline - Fierce Biotech","headline":"Artios Pharma secures $115M series D to ramp up clinical efforts with DNA damage response pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOdHhxeUhkcGdxVHpIeW0xRGQyUWZLUUpLdHpyX294Y1RzT2F4LVZfcTN3NGswY25Qci1sWnFnMWY0TFZScmxjX1Z3UEg4Mm1XX2RRYUtmcWRnaWpQWG8yb2VOODV5cUQwT0ZlRENEOGhPUTZPSWdCY2R0ZHMwSTVRcXFONEpaaDhrVzViQXNaN1U0ZXpZSEE?oc=5","date":"2025-11-17","type":"pipeline","source":"BioPharma Dive","summary":"A ‘DNA damage repair’ drugmaker raises $115M for cancer treatments - BioPharma Dive","headline":"A ‘DNA damage repair’ drugmaker raises $115M for cancer treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQTzNjSGliNFEwcG92ZDZ3aGNfbnVxaFRkZWcwdzBITkxtUzdXcm93UkZmRlJha093ejF6ZGNxOHJOTU1GV0NJazE2NWhYQVlRT2cwNDgyZHVSUlFla3J3OTdXOER1RWhaZWJhWU9sR1lZOEhXbVR1RWFlVUJ4TkwxY1N1OUthd3VhZTV5aGk1a3BaUVZCY1BiYXJmN21qWVnSAaQBQVVfeXFMTUhOLWtueklFTWQtRmd2WFNXY01JWjlWaEVxY0pZbkl0TTZjaDNnb2w1Skk5NjJnSE14TjJXWGcxMXhvUTcySEgxNTI4cnhhRHJkWXhfLWZrX0owa21SWVJPWXZvYTR6MDZOWTF1bXF2RU5xOUE0N0xIYWU1NXFQX3BZQkZ5N0ZVeWpKbkxCYjBaQzJraG9GNVRnSjMwY0xlRUlWblA?oc=5","date":"2025-11-17","type":"pipeline","source":"Pulse 2.0","summary":"Artios: $115 Million Series D Raised To Advance Late-Stage DDR Oncology Pipeline - Pulse 2.0","headline":"Artios: $115 Million Series D Raised To Advance Late-Stage DDR Oncology Pipeline - Pulse 2.0","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOMUY3ZHZlVXVsclJFTmNLSmM5dzVtOVlXTmxXYWhES0xGTFJCOEhrcDJiVEJmbG5NaHR4eEhSbnBveGxtb2xIOGZPb3daV0dneTVlSjlPdFNiZnI5bERlcVRQazkyMjd2ZF82RV9FcDBxamlqOHRHWXlxTDFxekg3bFhUSUk1TWRNLTNaMU1yb2MwckNZYXlvVTdJQml4RUVfVm5kY3RRcHR1Mi1LcGZR?oc=5","date":"2024-02-07","type":"pipeline","source":"citybiz","summary":"Artios Pharma Appoints Christine Silverstein as Chief Financial Officer - citybiz","headline":"Artios Pharma Appoints Christine Silverstein as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQV3hDV2FreDZrUEh5U2c4SElPY0pkbUtSZ2huVFNDc0ZpQ0RmSHdQNDluMkFaMkhYQ2FOTXhndW4zbjI2Z3plMDhLRWZ0UlhLZDZJa3VLdzJjbXRwczljSnVTZnhHSU9ieS1MN3E4bzdwdUdJOVNPZTVBdk10R0xpdU1HcmU3NGJmTHBWd3NxTzZwWFpPYVhBcWxJdzVjUQ?oc=5","date":"2021-04-07","type":"pipeline","source":"pharmaphorum","summary":"Novartis expands in radio-oncology again with $1.3bn Artios alliance - pharmaphorum","headline":"Novartis expands in radio-oncology again with $1.3bn Artios alliance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNSW1SbWlmNXMzSzdxdGhva09ibTBKRE5EbmtIVHU2TmRpbjFMSnlVNFJieVZRcTZGWkVHZkpPR2h5b0JPZGFmMFBXN0JRZnF1Z2RBVmNCV2k3RlREMXZKcHRHU0l0M0xWcy13SHF1cHY2ZDN0T1lweWQ1QVJYZUhMbkJheExETV9QQWFCOUQ3V29WYWRJb1pTRFFPeVRiSzJFbU1WUzloVlVTaHc1N0lXSldtcFo4cGg2aERfelI0UG5PdFFpNWs3WWRST3JtWHBWWnJIRWJ3?oc=5","date":"2020-12-03","type":"deal","source":"Reuters","summary":"Merck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs - Reuters","headline":"Merck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":2,"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}